Bacteremic nosocomial pneumonia caused by Acinetobacter baumannii and Acinetobacter nosocomialis: a single or two distinct clinical entities?
|
|
- Shana O’Neal’
- 5 years ago
- Views:
Transcription
1 ORIGINAL ARTICLE INFECTIOUS DISEASES Bacteremic nosocomial pneumonia caused by Acinetobacter baumannii and Acinetobacter nosocomialis: a single or two distinct clinical entities? Y.-T. Lee 1,2,3, S.-C. Kuo 1,4, S.-P. Yang 2,5, Y.-T. Lin 1,2,5, D.-H. Chiang 2,6, F.-C. Tseng 4, T.-L. Chen 1,2,5 and C.-P. Fung 1,2,5 1) Institute of Clinical Medicine, 2) School of Medicine, National Yang-Ming University, Taipei, 3) Department of Medicine, Chutung Veterans Hospital, Hsinchu County, 4) National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli County, 5) Division of Infectious Diseases and 6) Department of Critical Care Medicine, Taipei Veterans General Hospital, Taipei, Taiwan Abstract The phenotypically indistinguishable Acinetobacter baumannii and Acinetobacter nosocomialis have become leading pathogens causing nosocomial pneumonia in critically ill patients. A. baumannii and A. nosocomialis nosocomial pneumonias were grouped as a single clinical entity previously. This study aimed to determine whether they are the same or a different clinical entity. A total of 121 patients with A. baumannii and 131 with A. nosocomialis bacteremic nosocomial pneumonia were included during an 8-year period. Despite the similar Charlson co-morbidity scores at admission, patients with A. baumannii pneumonia were more likely to have abnormal haematological findings, lobar pneumonia, significantly higher Acute Physiology and Chronic Health Evaluation II scores and higher frequency of shock at the onset of bacteraemia than those with A. nosocomialis pneumoni. A. baumannii isolates were resistant to more classes of antimicrobials, except colistin, and therefore the patients with A. baumannii pneumonia were more likely to receive inappropriate antimicrobial therapy. The 14-day mortality was significantly higher in patients with A. baumannii pneumonia (34.7% vs. 15.3%, p 0.001). A. baumannii was an independent risk factor for mortality (OR, 2.03; 95% CI, ; p 0.035) in the overall cohort after adjustment for other risk factors for death, including inappropriate antimicrobial therapy. The results demonstrated the difference in clinical presentation, microbial characteristics and outcomes between A. baumannii and A. nosocomialis nosocomial pneumonia, and supported that they are two distinct clinical entities. Keywords: Acinetobacter baumannii, Acinetobacter nosocomialis, antimicrobial therapy, mortality, pneumonia Original Submission: 4 May 2012; Revised Submission: 2 July 2012; Accepted: 8 July 2012 Editor: M. Paul Article published online: 12 July 2012 Clin Microbiol Infect 2013; 19: /j x Corresponding author: T.-L. Chen, Division of Infectious Diseases, Taipei Veterans General Hospital, No. 201, Section 2, Shih-Pai Road, Taipei, 11217, Taiwan tecklayyy@yahoo.com.tw Introduction The phenotypically indistinguishable Acinetobacter baumannii, Acinetobacter nosocomialis (formerly Acinetobacter genomic species 13TU) and Acinetobacter pittii (formerly Acinetobacter genomic species 3) are grouped as the A. baumannii (Ab) group [1,2] and have emerged as leading pathogens of nosocomial pneumonia in critically ill patients [3,4]. To date, there is controversy over whether Ab group pneumonia results in higher mortality [5 7] or inappropriate antimicrobial therapy affects the mortality of patients with Ab group pneumonia [8,9]. The pneumonia caused by phenotypically identified A. baumannii described in many studies actually comprises pneumonia caused by either one of the Acinetobacter species in the Ab group [8,10]. Recently, several studies reported that there are differences in antimicrobial resistance and outcome between A. baumannii and other Acinetobacter species in the Ab group [11 13]. It is unclear whether pneumonia caused by these different Acinetobacter species can be considered as a single clinical entity, or they are different in clinical presentation, microbial characteristics and outcomes. Acinetobacter baumannii and A. nosocomialis are the two most commonly isolated Acinetobacter species in clinical settings [14] and account for more than 80% of infections caused by the Ab group [11,12,15,16]. In this study, the clinical Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases
2 CMI Lee et al. Pneumonia caused by Ab group 641 characteristics, microbiological findings and final outcomes of a large number of patients with bacteraemic nosocomial pneumonia caused by A. baumannii and A. nosocomialis were analysed to determine whether nosocomial pneumonia caused by these two Acinetobacter species is a single or distinct clinical entity. Materials and Methods Study population The study was conducted at Taipei Veterans General Hospital (T-VGH) during an 8-year period from July 2000 to August T-VGH is a 2900-bed tertiary-care teaching hospital located in Taipei, Taiwan. Charts were reviewed for all patients with at least one positive blood culture for A. baumannii or A. nosocomialis who had symptoms and signs of infection. Only the first blood culture from patients with two or more positive blood cultures was included. The criteria for inclusion [17] in this study were (i) at least one positive respiratory sample (sputum, bronchoalveolar lavage or pleural effusion) for the Ab group obtained within 48 h before or after the first positive blood culture; (ii) a clinical course compatible with the diagnosis of pneumonia, including a new pulmonary infiltrate plus one additional criterion (fever 38 C, blood leukocytosis cells/mm 3 or leucopenia 3000 cells/mm 3 ), together with one or more of the following conditions: new cough, change of color of sputum, chest pain, and dyspnoea; and (iii) that the positive blood culture was not related to another source of infection. Patients <18 years of age and those with incomplete medical records were excluded. The protocol was approved by the T-VGH Institutional Review Board with a waiver of informed consent. Microbiological studies The presumptive identification of the isolates to the level of the Ab group was performed with the API ID 32 GN system (biomérieux, Marcy l Etoile, France) or Vitek 2 system (bio- Mérieux). A multiplex-pcr method was used to identify A. baumannii to the genomic species level [18]. Isolates identified as non- A. baumannii species of Acinetobacter were identified to the genomic species level by 16S 23S ribosomal DNA intergenic spacer sequence analysis [19]. Antimicrobial susceptibilities were determined by the agar dilution method according to the Clinical Laboratory Standards Institute (CLSI) [20]. Multidrug resistance was defined as resistance to three or more of the following classes of antimicrobial agents: antipseudomonal cephalosporins, antipseudomonal carbapenems, ampicillin/sulbactam, fluoroquinolones and aminoglycosides [1]. Data collection Medical records were reviewed to extract clinical information, including demographic characteristics, underlying diseases, Charlson [21] co-morbidity score, duration of stay in an intensive care unit (ICU), length of hospital stay, time of receipt, dose and route of administration of individual antimicrobials, the mechanical ventilation, central venous catheters, a nasogastric tube, or a foley catheter at the time of onset of bacteremi A. Community-acquired pneumonia (CAP), healthcare-associated pneumonia (HCAP), nosocomial pneumonia and ventilator-associated pneumonia (VAP) were defined according to the 2005 American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) guidelines [22]. Chronic lung diseases other than chronic obstructive pulmonary disease (COPD) included asthma, bronchiectasis, pulmonary fibrosis and old pulmonary tuberculosis [23]. Immunosuppressive therapy was defined as receipt of cytotoxic agents within 6 weeks, or corticosteroids at a dosage equivalent to or higher than 10 mg of prednisolone daily for more than 5 days within 4 weeks prior to the onset of bacteremi A. Neutropenia was defined as an absolute neutrophil count <500 per mm 3. Recent surgery was defined as operations performed within 4 weeks prior to the onset of bacteremi A. Chronic kidney disease was defined as an estimated glomerular filtration rate (egfr) <60 ml/min/1.73 m 2. Polymicrobial bacteraemia was defined as isolation of one or more microorganisms other than A. baumannii or A. nosocomialis from blood during the same bacteraemic episode. The illness severity was evaluated using the Acute Physiology and Chronic Health Evaluation II (APACHE II) score [24] within 24 h prior to bacteraemia onset. Appropriate antimicrobial therapy was defined as administration of at least one antimicrobial agent, to which the causative pathogen was susceptible, within 48 h after the onset of bacteraemia, with an approved route and dosage for endorgan(s) function. Antimicrobial therapy that did not meet this definition was considered as inappropriate. Monotherapy with an aminoglycoside was not considered as an appropriate therapy. The primary outcome measure was all-cause 14-day mortality following the onset of A. baumannii or A. nosocomialis bacteraemia, respectively. Statistical analysis To assess differences, the chi-square test with Yate s correction or Fisher s exact test was used to compare the discrete variables; the Student s t-test or Mann Whitney rank sum test was used to analyse continuous variables. Logistic regression models were used to explore independent risk factors for 14-day mortality. Univariate analyses were per-
3 642 Clinical Microbiology and Infection, Volume 19 Number 7, July 2013 CMI formed separately for each of the risk factor variables to ascertain the odds ratio (OR) and 95% confidence interval (CI). All biologically plausible variables with a p value of 0.20 in the univariate analysis were considered for inclusion in the logistic regression model for the multivariate analysis. A backward selection process was utilized. Time to mortality was analysed using Kaplan Meier survival analysis. A p value <0.05 was considered statistically significant. All the analyses were processed with the Statistical Package for the Social Sciences (SPSS) software version 18.0 (SPSS, Chicago, IL, USA). Results During the study period 770 patients were found to have had at least one episode of bacteraemia caused by the Ab group. Following genomic species analysis, 353 (45.8%) and 333 (43.2%) patients were identified as having had bacteraemia caused by A. baumannii and A. nosocomialis, respectively. We excluded 129 patients with polymicrobial bacteraemia and 288 patients with a positive blood culture attributable to another source of infection. Eight patients with community- Demographic or characteristic A. baumannii (n = 121) A. nosocomialis (n = 131) p value Age, in years 74.0 (58 80) 77 (65 83) 0.05 Gender, male 93 (76.9) 101 (77.1) >0.99 Acquired in ICU 86 (71.1) 92 (70.2) 0.99 Ventilator-associated pneumonia 85 (70.2) 93 (71.0) >0.99 Days of hospitalization prior to culture 23 (11 40) 17 (11 31) 0.14 Co-morbidity Charlson co-morbidity score 3 (2 5) 3 (2 5) 0.77 Hypertension 57 (47.1) 79 (60.3) 0.05 Coronary artery disease 22 (18.2) 24 (18.3) >0.99 Congestive heart failure 21 (17.4) 22 (16.5) >0.99 Cerebral vascular disease 27 (22.3) 34 (26.0) 0.60 COPD 28 (23.1) 40 (30.5) 0.24 Other chronic lung disease 18 (14.9) 14 (10.7) 0.42 Alcoholism 15 (12.4) 7 (5.3) 0.08 Liver cirrhosis 8 (6.6) 10 (7.6) 0.94 Chronic kidney disease 38 (31.4) 37 (28.2) 0.68 Type 2 diabetes mellitus 40 (33.1) 47 (35.9) 0.74 Collagen vascular disease 10 (8.3) 2 (1.5) 0.03 TABLE 1. Demographic and clinical characteristics of patients with bacteraemic nosocomial pneumonia caused by Acinetobacter baumannii and Acinetobacter nosocomialis Usage of immunosupressants Cytotoxic chemotherapy 19 (15.7) 13 (9.9) 0.24 Corticosteroids 24 (19.8) 13 (9.9) 0.04 Malignancy 41 (33.9) 39 (29.8) 0.57 Recent surgery 38 (31.4) 52 (39.7) 0.22 Trauma 4 (3.3) 11 (8.4) 0.15 Procedure a Central venous catheter 80 (66.1) 83 (63.4) 0.75 Foley catheter 89 (73.6) 93 (71.0) 0.75 Haemodialysis 14 (11.6) 13 (9.9) 0.83 Nasogastric tube 111 (91.7) 100 (76.3) Thoracic drain 7 (5.8) 12 (9.2) 0.44 Endotracheal tube or tracheostomy 103 (85.1) 103 (78.6) 0.24 Mechanical ventilation 90 (74.4) 94 (71.8) 0.74 Shock a 77 (63.6) 62 (47.3) 0.01 Laboratory parameters a WBC count <4000/mm 3, >12 000/mm 3, or >10% bands 96 (70.6) 75 (56.4) 0.02 Haemoglobin, g/dl 9.2 ( ) 10.1 ( ) <0.001 Platelet count, 10 3 cells/mm ( ) 170 (96 255) 0.04 APACHE II score a 26 (21 34) 24 (18 30) Radiological features Lobar consolidation 13 (10.7) 4 (3.1) 0.03 Bilateral radiological involvement 89 (73.6) 93 (71.0) 0.75 Pleural effusion 40 (33.1) 46 (35.1) 0.83 Appropriate antimicrobial therapy 32 (26.4) 69 (52.7) <0.001 Outcome 14-day mortality 42 (34.7) 20 (15.3) In-hospital mortality 79 (65.3) 53 (40.5) <0.001 Time to death, days 9 (1 32) 27 ( ) Data are median value (interquartile range) for continuous variables and number of cases (%) for categorical variables. ICU, intensive care units; COPD, chronic obstructive pulmonary disease; APACHE, Acute Physiology and Chronic Health Evaluation; WBC, white blood cell. a At the time the blood culture was obtained.
4 CMI Lee et al. Pneumonia caused by Ab group 643 acquired A. baumannii pneumonia, which is a distinct clinical entity, were excluded [23,25]. We also excluded nine patients with HCAP (seven caused by A. baumannii and two by A. nosocomialis). The final population that met the criteria for entry into the study consisted of 121 patients with A. baumannii and 131 patients with A. nosocomialis nosocomial pneumonia. The demographic and clinical characteristics of the study patients are summarized in Table 1. Patients with A. baumannii had more collagen vascular diseases, and more frequently received corticosteroids and had nasogastric tubes than those with A. nosocomialis. The Charlson co-morbidity scores on admission were similar for the two Acinetobacter species. However, patients with A. baumannii had significantly higher APACHE II scores (p 0.003) and more frequently presented with shock at the time positive blood cultures were obtained. Patients with A. baumannii had lower haemoglobin levels and platelet counts, and more frequently presented with leukocytosis or leucopenia, but they did not have more haematological malignancy (data not shown). Pulmonary lobar consolidation was significantly more frequent in patients with A. baumannii pneumonia (p 0.03), while pleural effusion and bilateral lung involvement were about the same with both Acinetobacter species. The antimicrobial susceptibility profiles of the clinical isolates of A. baumannii and A. nosocomialis are shown in Table 2. A. baumannii exhibited significantly higher rates of resistance to all antimicrobials tested, with the exception of colistin. None of the A. baumannii isolates were resistant to colistin. In contrast, 26.7% of the A. nosocomialis isolates were resistant to colistin (p <0.001). Patients with bacteraemic pneumonia caused by A. baumannii were accordingly more likely to receive inappropriate antimicrobial therapy. The 14-day mortality was significantly higher for patients with bacteraemic pneumonia caused by A. baumannii than for A. nosocomialis (34.7% vs. 15.3%, p 0.001). The median time TABLE 2. Comparison of antimicrobial susceptibilities of Acinetobacter baumannii and Acinetobacter nosocomialis isolates Antimicrobial agent Resistance, n (%) A. baumannii (n = 121) A. nosocomialis (n = 131) p value Amikacin 108 (89.3) 53 (40.5) <0.001 Gentamicin 110 (90.9) 84 (64.1) <0.001 Ceftazidime 110 (90.9) 39 (29.8) <0.001 Cefepime 82 (67.8) 31 (23.7) <0.001 Ampicillin/sulbactam 68 (56.2) 40 (30.5) <0.001 Ciprofloxacin 111 (91.7) 15 (11.5) <0.001 Imipenem 49 (40.5) 28 (21.4) Tigecycline 18 (14.9) 7 (5.3) 0.02 Colistin 0 (0) 35 (26.7) <0.001 Multidrug resistance 112 (92.6) 63 (48.1) <0.001 to death was significantly shorter for A. baumannii (9 days; interquartile range, 1 32 days) than A. nosocomialis pneumonia (27 days; interquartile range, days) (p 0.003). Kaplan Meier survival curves reflected the early occurrence of death within a few days following pneumonia for patients with A. baumannii. This was followed by slightly higher rates of death for A. baumannii than A. nosocomialis species thereafter (p <0.001, by log-rank test) (Fig. 1). In order to clarify the influence of different Acinetobacter species on 14-day mortality, multivariate logistic regression analysis was performed for the overall cohort to identify independent risk and protective factors for mortality (Table 3). Notably, A. baumannii was an independent risk factor for mortality (OR, 2.03; 95% CI, ; p 0.035). Discussion This study clearly demonstrates significant differences in the clinical features, microbial characteristics and outcome of bacteraemic nosocomial pneumonia caused by A. baumannii and A. nosocomialis. Compared with patients with A. nosocomialis pneumonia, patients with A. baumannii pneumonia have more collagen vascular disease and use of corticosteroids. Patients with A. baumannii were significantly more likely to have more severe illness as determined by APACHE II score, greater frequency of shock, abnormal haematological findings, lobar pneumonia, antimicrobial resistance, inappropriate use of antimicrobials, shorter time to death and higher mortality. These findings support the concept that bacteraemic pneumonias caused by A. baumannii and A. nosocomialis should be considered as two distinct clinical entities. The shorter time to death and higher mortality of patients infected with A. baumannii compared with A. nosocomialis may be attributed to an unfavourable underlying disease of the Survival probability Survival functions 5 10 Days of follow-up A. nosocomialis A. baumannii FIG. 1. Kaplan Meier survival curves for patients with Acinetobacter baumannii and Acinetobacter nosocomialis bacteraemic nosocomial pneumonia. 15
5 644 Clinical Microbiology and Infection, Volume 19 Number 7, July 2013 CMI Demographic or characteristic Univariate analysis Odds ratio (95% CI) p Multivariable analysis Odds ratio (95% CI) p Acinetobacter baumannii 2.95 ( ) < ( ) Bilateral radiological involvement 1.83 ( ) ( ) Chronic lung diseases other than COPD 1.74 ( ) Usage of cytotoxic chemotherapy 1.74 ( ) Usage of corticosteroids 3.40 ( ) ( ) Presence of central venous catheter 1.62 ( ) Presence of nasogastric tube 2.11 ( ) Malignancy 1.66 ( ) ( ) Inappropriate antibiotics 3.68 ( ) < ( ) TABLE 3. Logistic regression analysis of predictors for 14-day mortality among patients with Acinetobacter baumannii and Acinetobacter nosocomialis bacteraemic nosocomial pneumonia CI, confidence interval; COPD, chronic obstructive pulmonary disease. patients, higher frequency of inappropriate antimicrobial therapy in the former group and possibly higher pathogenicity of A. baumannii [11,12]. Our study showed that although the chronic co-morbidity scores of patients at admission were similar between the two groups, pneumonia caused by A. baumannii was more severe than that caused by A. nosocomialis at the onset of bacteremi A. In addition, A. baumannii is an independent risk factor for mortality after adjustment for other risk factors for death, including inappropriate antimicrobial therapy. The result once again indicated a higher pathogenicity of A. baumannii. Based on the results one could assume that previous papers reporting a negligible attributable mortality of the Ab group [10] might include a large proportion of patients with infections due to A. nosocomialis, while papers reporting a considerable attributable mortality [6] might include mostly patients with real A. baumannii infections. Our findings that higher resistance rates of all antimicrobials except colistin were observed in A. baumannii isolates than in A. nosocomialis [11,15,26] were responsible for the increasing chance of receiving an inappropriate antimicrobial therapy in patients infected with A. baumannii. This might also contribute to the higher mortality in A. baumannii, especially in those with higher APACHE II scores [27]. In conclusion, we recommend that nosocomial pneumonia caused by A. baumannii and A. nosocomialis should be considered as two different clinical entities. Acknowledgements The authors wish to express their appreciation to Calvin M. Kunin for his critical review of the manuscript. Transparency Declaration This study was supported by grants from the Taipei Veterans General Hospital (V101E4-003 and V101C-021), the National Science Council (NSC B MY3) and the Yen Tjing Ling Medical Foundation (CI ). The authors declare that they have no conflicts of interest. References 1. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008; 21: Espinal P, Seifert H, Dijkshoorn L, Vila J, Roca I. Rapid and accurate identification of genomic species from the Acinetobacter baumannii (Ab) group by MALDI-TOF MS. Clin Microbiol Infect 2011; Oct 13; [Epub ahead of print]. doi: /j x. 3. Joly-Guillou ML. Clinical impact and pathogenicity of Acinetobacter. Clin Microbiol Infect 2005; 11: Falagas ME, Karveli EA. The changing global epidemiology of Acinetobacter baumannii infections: a development with major public health implications. Clin Microbiol Infect 2007; 13: Falagas ME, Bliziotis IA, Siempos II. Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies. Crit Care 2006; 10: R Falagas ME, Kopterides P, Siempos II. Attributable mortality of Acinetobacter baumannii infection among critically ill patients. Clin Infect Dis 2006; 43: Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006; 42: Joung MK, Kwon KT, Kang CI et al. Impact of inappropriate antimicrobial therapy on outcome in patients with hospital-acquired pneumonia caused by Acinetobacter baumannii. J Infect 2010; 61: Garnacho-Montero J, Ortiz-Leyba C, Fernandez-Hinojosa E et al. Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Intensive Care Med 2005; 31: Garnacho J, Sole-Violan J, Sa-Borges M, Diaz E, Rello J. Clinical impact of pneumonia caused by Acinetobacter baumannii in intubated patients: a matched cohort study. Crit Care Med 2003; 31: Chuang YC, Sheng WH, Li SY et al. Influence of genospecies of Acinetobacter baumannii complex on clinical outcomes of patients with acinetobacter bacteremia. Clin Infect Dis 2011; 52: Lee NY, Chang TC, Wu CJ et al. Clinical manifestations, antimicrobial therapy, and prognostic factors of monomicrobial Acinetobacter baumannii complex bacteremia. J Infect 2010; 61: Wisplinghoff H, Paulus T, Lugenheim M et al. Nosocomial bloodstream infections due to Acinetobacter baumannii, Acinetobacter pittii and Acinetobacter nosocomialis in the United States. J Infect 2012; 64:
6 CMI Lee et al. Pneumonia caused by Ab group Wisplinghoff H, Hippler C, Bartual SG et al. Molecular epidemiology of clinical Acinetobacter baumannii and Acinetobacter genomic species 13TU isolates using a multilocus sequencing typing scheme. Clin Microbiol Infect 2008; 14: Lee YT, Huang LY, Chiang DH et al. Differences in phenotypic and genotypic characteristics among imipenem-non-susceptible Acinetobacter isolates belonging to different genomic species in Taiwan. Int J Antimicrob Agents 2009; 34: Lee YC, Huang YT, Tan CK et al. Acinetobacter baumannii and Acinetobacter genospecies 13TU and 3 bacteraemia: comparison of clinical features, prognostic factors and outcomes. J Antimicrob Chemother 2011; 66: Magret M, Lisboa T, Martin-Loeches I et al. Bacteremia is an independent risk factor for mortality in nosocomial pneumonia: a prospective and observational multicenter study. Crit Care 2011; 15: R Chen TL, Siu LK, Wu RC et al. Comparison of one-tube multiplex PCR, automated ribotyping and intergenic spacer (ITS) sequencing for rapid identification of Acinetobacter baumannii. Clin Microbiol Infect 2007; 13: Chang HC, Wei YF, Dijkshoorn L, Vaneechoutte M, Tang CT, Chang TC. Species-level identification of isolates of the Acinetobacter calcoaceticus-acinetobacter baumannii complex by sequence analysis of the 16S-23S rrna gene spacer region. J Clin Microbiol 2005; 43: Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twenty-first informational supplement. CLSI document M100-S21. Wayne, PA: Clinical and Laboratory Standards Institute, Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: Leung WS, Chu CM, Tsang KY, Lo FH, Lo KF, Ho PL. Fulminant community-acquired Acinetobacter baumannii pneumonia as a distinct clinical syndrome. Chest 2006; 129: Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: Chen MZ, Hsueh PR, Lee LN, Yu CJ, Yang PC, Luh KT. Severe community-acquired pneumonia due to Acinetobacter baumannii. Chest 2001; 120: Liang-Yu C, Kuo SC, Liu CY et al. Difference in imipenem, meropenem, sulbactam, and colistin nonsusceptibility trends among three phenotypically undifferentiated Acinetobacter baumannii complex in a medical center in Taiwan, J Microbiol Immunol Infect 2011; 44: Lee YT, Kuo SC, Yang SP et al. Impact of appropriate antimicrobial therapy on mortality associated with Acinetobacter baumannii bacteremia: relation to severity of infection. Clin Infect Dis 2012; 55:
RISK FACTORS AND CLINICAL OUTCOMES OF MULTIDRUG-RESISTANT ACINETOBACTER BAUMANNII BACTEREMIA AT A UNIVERSITY HOSPITAL IN THAILAND
RISK FACTORS AND CLINICAL OUTCOMES OF MULTIDRUG-RESISTANT ACINETOBACTER BAUMANNII BACTEREMIA AT A UNIVERSITY HOSPITAL IN THAILAND Siriluck Anunnatsiri 1 and Pantipa Tonsawan 2 1 Division of Infectious
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationAvailable online at journal homepage:
Journal of Microbiology, Immunology and Infection (2012) 45, 108e112 Available online at www.sciencedirect.com journal homepage: www.e-jmii.com ORIGINAL ARTICLE Amino acid substitutions of quinolone resistance
More informationMDR Acinetobacter baumannii. Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta
MDR Acinetobacter baumannii Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta 1 The Armageddon recipe Transmissible organism with prolonged environmental
More informationUpdate on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia. Po-Ren Hsueh. National Taiwan University Hospital
Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia Po-Ren Hsueh National Taiwan University Hospital Ventilator-associated Pneumonia Microbiological Report Sputum from a
More information4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES
CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial
More informationPolymerase chain reaction assay for the detection of Acinetobacter baumannii in endotracheal aspirates from patients in the intensive care unit
Journal of Microbiology, Immunology and Infection (2011) 44, 106e110 available at www.sciencedirect.com journal homepage: www.e-jmii.com ORIGINAL ARTICLE Polymerase chain reaction assay for the detection
More informationInt.J.Curr.Microbiol.App.Sci (2017) 6(3):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 3 (2017) pp. 891-895 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.603.104
More informationSource: Portland State University Population Research Center (
Methicillin Resistant Staphylococcus aureus (MRSA) Surveillance Report 2010 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Health Authority Updated:
More informationUCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients
Background/methods: UCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients This guideline establishes evidence-based consensus standards for management
More informationReceived 23 May 2004/Returned for modification 31 August 2004/Accepted 11 October 2004
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 2005, p. 760 766 Vol. 49, No. 2 0066-4804/05/$08.00 0 doi:10.1128/aac.49.2.760 766.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationMono- versus Bitherapy for Management of HAP/VAP in the ICU
Mono- versus Bitherapy for Management of HAP/VAP in the ICU Jean Chastre, www.reamedpitie.com Conflicts of interest: Consulting or Lecture fees: Nektar-Bayer, Pfizer, Brahms, Sanofi- Aventis, Janssen-Cilag,
More informationEvaluating the Role of MRSA Nasal Swabs
Evaluating the Role of MRSA Nasal Swabs Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds February 28, 2017 2016 MFMER slide-1 Objectives Identify the pathophysiology of MRSA nasal colonization
More informationMultidrug-resistant Acinetobacter baumannii isolates in pediatric patients of a university hospital in Taiwan
MDRAB J Microbiol in Immunol pediatric patients Infect. 2007;40:406-410 Original Article Multidrug-resistant Acinetobacter baumannii isolates in pediatric patients of a university hospital in Taiwan Po-Yang
More informationChanging trends in clinical characteristics and antibiotic susceptibility of Klebsiella pneumoniae bacteremia
ORIGINAL ARTICLE Korean J Intern Med 2018;33:595-603 Changing trends in clinical characteristics and antibiotic susceptibility of Klebsiella pneumoniae Miri Hyun, Chang In Noh, Seong Yeol Ryu, and Hyun
More informationORIGINAL ARTICLE /j x
ORIGINAL ARTICLE 10.1111/j.1469-0691.2005.01305.x Pandrug-resistant Pseudomonas aeruginosa among hospitalised patients: clinical features, risk-factors and outcomes C. Y. Wang 1, J. S. Jerng 1, K. Y. Cheng
More informationWhat does multiresistance actually mean? Yohei Doi, MD, PhD University of Pittsburgh
What does multiresistance actually mean? Yohei Doi, MD, PhD University of Pittsburgh Disclosures Merck Research grant Clinical context of multiresistance Resistance to more classes of agents Less options
More informationManagement of Hospital-acquired Pneumonia
Management of Hospital-acquired Pneumonia Adel Alothman, MB, FRCPC, FACP Asst. Professor, COM, KSAU-HS Head, Infectious Diseases, Department of Medicine King Abdulaziz Medical City Riyadh Saudi Arabia
More informationClinical Characteristics, Antimicrobial Susceptibilities, andoutcomesofpatientswithchryseobacterium indologenes Bacteremia in an Intensive Care Unit
Jpn. J. Infect. Dis., 64, 520-524, 2011 Short Communication Clinical Characteristics, Antimicrobial Susceptibilities, andoutcomesofpatientswithchryseobacterium indologenes Bacteremia in an Intensive Care
More informationMethicillin-Resistant Staphylococcus aureus Nasal Swabs as a Tool in Antimicrobial Stewardship
Methicillin-Resistant Staphylococcus aureus Nasal Swabs as a Tool in Antimicrobial Stewardship Natalie R. Tucker, PharmD Antimicrobial Stewardship Pharmacist Tyson E. Dietrich, PharmD PGY2 Infectious Diseases
More informationDR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA
DR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA The good old days The dread (of) infections that used to rage through the whole communities is muted Their retreat
More informationCost high. acceptable. worst. best. acceptable. Cost low
Key words I Effect low worst acceptable Cost high Cost low acceptable best Effect high Fig. 1. Cost-Effectiveness. The best case is low cost and high efficacy. The acceptable cases are low cost and efficacy
More informationDetection and Quantitation of the Etiologic Agents of Ventilator Associated Pneumonia in Endotracheal Tube Aspirates From Patients in Iran
Letter to the Editor Detection and Quantitation of the Etiologic Agents of Ventilator Associated Pneumonia in Endotracheal Tube Aspirates From Patients in Iran Mohammad Rahbar, PhD; Massoud Hajia, PhD
More informationThe International Collaborative Conference in Clinical Microbiology & Infectious Diseases
The International Collaborative Conference in Clinical Microbiology & Infectious Diseases PLUS: Antimicrobial stewardship in hospitals: Improving outcomes through better education and implementation of
More informationAppropriate Antibiotic Administration in Critically Ill Patients with Pneumonia
Research Paper Appropriate Antibiotic Administration in Critically Ill Patients with Pneumonia R. A. KHAN, M. M. BAKRY 1 AND F. ISLAHUDIN 1 * Hospital SgBuloh, Jalan Hospital, 47000 SgBuloh, Selangor,
More informationSuitability of Antibiotic Treatment for CAP (CAPTIME) The duration of antibiotic treatment in community acquired pneumonia (CAP)
STUDY PROTOCOL Suitability of Antibiotic Treatment for CAP (CAPTIME) Purpose The duration of antibiotic treatment in community acquired pneumonia (CAP) lasts about 9 10 days, and is determined empirically.
More informationSystematic Review of Clinical PK-PD Studies of Antibacterials. Alex McAleenan Julian Higgins Alasdair MacGowan William Hope Johan Mouton
Systematic Review of Clinical PK-PD Studies of Antibacterials Alex McAleenan Julian Higgins Alasdair MacGowan William Hope Johan Mouton Background It has been suggested that there are problems with current
More informationAntibiotic utilization and Pseudomonas aeruginosa resistance in intensive care units
NEW MICROBIOLOGICA, 34, 291-298, 2011 Antibiotic utilization and Pseudomonas aeruginosa resistance in intensive care units Vladimíra Vojtová 1, Milan Kolář 2, Kristýna Hricová 2, Radek Uvízl 3, Jan Neiser
More informationRisk factors for multidrug-resistant Pseudomonas aeruginosa acquisition. Impact of antibiotic use in a double case control study
Eur J Clin Microbiol Infect Dis (2010) 29:335 339 DOI 10.1007/s10096-009-0850-1 BRIEF REPORT Risk factors for multidrug-resistant Pseudomonas aeruginosa acquisition. Impact of antibiotic use in a double
More informationESISTONO LE HCAP? Francesco Blasi. Sezione Medicina Respiratoria Dipartimento Toraco Polmonare e Cardiocircolatorio Università degli Studi di Milano
ESISTONO LE HCAP? Francesco Blasi Sezione Medicina Respiratoria Dipartimento Toraco Polmonare e Cardiocircolatorio Università degli Studi di Milano Community-acquired pneumonia (CAP): Management issues
More informationKey words: antibiotics; intensive care; mechanical ventilation; outcomes; pneumonia; resistance
Clinical Importance of Delays in the Initiation of Appropriate Antibiotic Treatment for Ventilator-Associated Pneumonia* Manuel Iregui, MD; Suzanne Ward, RN; Glenda Sherman, RN; Victoria J. Fraser, MD;
More informationDoes Early and Appropriate Antibiotic Administration Improve Mortality in Emergency Department Patients with Severe Sepsis or Septic Shock?
References and Literature Grading Does Early and Appropriate Antibiotic Administration Improve Mortality in Emergency Department Patients with Severe Sepsis or Septic Shock? (9/6/2015) 1. Dellinger, R.P.,
More informationCarbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis
ORIGINAL ARTICLE BACTERIOLOGY Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis E. V. Lemos 1,3, F. P. de la Hoz 2, T. R. Einarson
More informationOPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS
HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA
More informationPSEUDOMONAS AERUGINOSA IN THE ETIOLOGY OF PAEDIATRIC HEALTHCARE-ASSOCIATED INFECTIONS
Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 11 (60) No. 1-2018 PSEUDOMONAS AERUGINOSA IN THE ETIOLOGY OF PAEDIATRIC HEALTHCARE-ASSOCIATED INFECTIONS P.C. CHIRIAC
More informationIs Cefazolin Inferior to Nafcillin for Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia?
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 2011, p. 5122 5126 Vol. 55, No. 11 0066-4804/11/$12.00 doi:10.1128/aac.00485-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Is Cefazolin
More informationSustaining an Antimicrobial Stewardship
Sustaining an Antimicrobial Stewardship Much needless expense, untoward effect, harm and disappointment can be prevented by better judgment in the use of antimicrobials Whitney A. Jones, PharmD Antimicrobial
More informationEpidemiology of early-onset bloodstream infection and implications for treatment
Epidemiology of early-onset bloodstream infection and implications for treatment Richard S. Johannes, MD, MS Marlborough, Massachusetts Health care-associated infections: For over 35 years, infections
More informationLin M. Riccio, Kimberley A. Popovsky, Tjasa Hranjec, Amani D. Politano, Laura H. Rosenberger, Kristin C. Tura, and Robert G.
SURGICAL INFECTIONS Volume 15, Number 4, 2014 ª Mary Ann Liebert, Inc. DOI: 10.1089/sur.2012.077 Association of Excessive Duration of Antibiotic Therapy for Intra-Abdominal Infection with Subsequent Extra-Abdominal
More informationWhat is pneumonia? Infection of the lung parenchyma Causative agents include bacteria, viruses, fungi, protozoa.
Pneumonia What is pneumonia? Infection of the lung parenchyma Causative agents include bacteria, viruses, fungi, protozoa www.netmedicine.com/xray/xr.htm Definition acute infectious disease, etiology usually
More informationAntimicrobial stewardship in managing septic patients
Antimicrobial stewardship in managing septic patients November 11, 2017 Samuel L. Aitken, PharmD, BCPS (AQ-ID) Clinical Pharmacy Specialist, Infectious Diseases slaitken@mdanderson.org Conflict of interest
More informationVancomycin-resistant enterococcal bacteremia: comparison of clinical features and outcome between Enterococcus faecium and Enterococcus faecalis
J Microbiol Immunol Infect. 2008;41:124-129 Vancomycin-resistant enterococcal bacteremia: comparison of clinical features and outcome between Enterococcus faecium and Enterococcus faecalis Yen-Yi Chou,
More informationCollege of Medicine, Chang Gung University, Taoyuan, Taiwan. Abstract
DOI 10.6314/JIMT.2016.27(2).05 2016 27 89-96 Combination Antibiotics for Gram-negative Bacteria in Patients with Healthcare-associated or Hospital-acquired Pneumonia with Severe Sepsis or Septic Shock
More informationIn Vitro Activities of Linezolid against Clinical Isolates of ACCEPTED
AAC Accepts, published online ahead of print on April 00 Antimicrob. Agents Chemother. doi:./aac.001-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationLack of Change in Susceptibility of Pseudomonas aeruginosa in a Pediatric Hospital Despite Marked Changes in Antibiotic Utilization
Infect Dis Ther (2014) 3:55 59 DOI 10.1007/s40121-014-0028-8 BRIEF REPORT Lack of Change in Susceptibility of Pseudomonas aeruginosa in a Pediatric Hospital Despite Marked Changes in Antibiotic Utilization
More informationSummary of unmet need guidance and statistical challenges
Summary of unmet need guidance and statistical challenges Daniel B. Rubin, PhD Statistical Reviewer Division of Biometrics IV Office of Biostatistics, CDER, FDA 1 Disclaimer This presentation reflects
More informationActive Bacterial Core Surveillance Site and Epidemiologic Classification, United States, 2005a. Copyright restrictions may apply.
Impact of routine surgical ward and intensive care unit admission surveillance cultures on hospital-wide nosocomial methicillin-resistant Staphylococcus aureus infections in a university hospital: an interrupted
More informationNosocomial Infections: What Are the Unmet Needs
Nosocomial Infections: What Are the Unmet Needs Jean Chastre, MD Service de Réanimation Médicale Hôpital Pitié-Salpêtrière, AP-HP, Université Pierre et Marie Curie, Paris 6, France www.reamedpitie.com
More informationInappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012
Inappropriate Use of Antibiotics and Clostridium difficile Infection Jocelyn Srigley, MD, FRCPC November 1, 2012 Financial Disclosures } No conflicts of interest } The study was supported by a Hamilton
More informationAntimicrobial Stewardship Program: Local Experience
Antimicrobial Stewardship Program: Local Experience Dr. WU Tak Chiu Associate Consultant Division of Infectious Diseases Department of Medicine Queen Elizabeth Hospital 18th January 2011 QUEEN ELIZABETH
More informationSafe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times
Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University
More informationFighting MDR Pathogens in the ICU
Fighting MDR Pathogens in the ICU Dr. Murat Akova Hacettepe University School of Medicine, Department of Infectious Diseases, Ankara, Turkey 1 50.000 deaths each year in US and Europe due to antimicrobial
More informationControl emergence of drug-resistant. Reduce costs
...PRESENTATIONS... Guidelines for the Management of Community-Acquired Pneumonia Richard E. Chaisson, MD Presentation Summary Guidelines for the treatment of community-acquired pneumonia (CAP) have been
More informationWitchcraft for Gram negatives
Witchcraft for Gram negatives Dr Subramanian S MD DNB MNAMS AB (Medicine, Infect Dis) Infectious Diseases Consultant Global Health City, Chennai www.asksubra.com Drug resistance follows the drug like a
More informationAcinetobacter Resistance in Turkish Tertiary Care Hospitals. Zeliha KOCAK TUFAN, MD, Assoc. Prof.
Acinetobacter Resistance in Turkish Tertiary Care Hospitals Zeliha KOCAK TUFAN, MD, Assoc. Prof. Acinetobacter Problem Countries that have reported hospital outbreaks of carbapenem-resistant Acinetobacter
More informationRisk factors of ciprofloxacin resistance in urinary Escherichia coli isolates
J Microbiol Immunol Infect. 2008;41:325-331 Risk factors of ciprofloxacin resistance in urinary Escherichia coli isolates Original Article Chun-Yu Lin 1, Shu-Hua Huang 2, Tun-Chieh Chen 1,3, Po-Liang Lu
More informationOutline. Antimicrobial resistance. Antimicrobial resistance in gram negative bacilli. % susceptibility 7/11/2010
Multi-Drug Resistant Organisms Is Combination Therapy the Way to Go? Sutthiporn Pattharachayakul, PharmD Prince of Songkhla University, Thailand Outline Prevalence of anti-microbial resistance in Acinetobacter
More informationIntra-Abdominal Infections. Jessica Thompson, PharmD, BCPS (AQ-ID) Infectious Diseases Pharmacy Clinical Specialist Renown Health April 19, 2018
Intra-Abdominal Infections Jessica Thompson, PharmD, BCPS (AQ-ID) Infectious Diseases Pharmacy Clinical Specialist Renown Health April 19, 2018 Select guidelines Mazuski JE, et al. The Surgical Infection
More informationAcinetobacter sp. isolates from emergency departments in two hospitals of South Korea
Journal of Medical Microbiology (2014), 63, 1363 1368 DOI 10.1099/jmm.0.075325-0 Acinetobacter sp. isolates from emergency departments in two hospitals of South Korea Ji-Young Choi, 1 3 Eun Ah Ko, 2 3
More informationTaiwan Crit. Care Med.2009;10: %
2008 30% 2008 2008 2004 813 386 07-346-8339 E-mail srwann@vghks.gov.tw 66 30% 2008 1 2008 2008 Intensive Care Med (2008)34:17-60 67 2 3 C activated protein C 4 5,6 65% JAMA 1995;273(2):117-23 Circulation,
More informationNEW ATS/IDSA VAP-HAP GUIDELINES
NEW ATS/IDSA VAP-HAP GUIDELINES MARK L. METERSKY, MD PROFESSOR OF MEDICINE UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE FARMINGTON, CT Mark Metersky, MD, FCCP, FACP is a Professor of Medicine at the University
More informationNewsflash: Hospital Medicine JOHN C. CHRISTENSEN, MD FACP AMERICAN COLLEGE OF PHYSICIANS, UTAH CHAPTER SCIENTIFIC MEETING FEBRUARY 10, 2017
Newsflash: Hospital Medicine JOHN C. CHRISTENSEN, MD FACP AMERICAN COLLEGE OF PHYSICIANS, UTAH CHAPTER SCIENTIFIC MEETING FEBRUARY 10, 2017 Newsflash: Fluoroquinolones Newsflash: Fluoroquinolones Don t
More informationSurveillance of Antimicrobial Resistance among Bacterial Pathogens Isolated from Hospitalized Patients at Chiang Mai University Hospital,
Original Article Vol. 28 No. 1 Surveillance of Antimicrobial Resistance:- Chaiwarith R, et al. 3 Surveillance of Antimicrobial Resistance among Bacterial Pathogens Isolated from Hospitalized Patients at
More informationHigh-Risk MDR clones news in treatment
Ferrara, 20 giugno 2013 High-Risk MDR clones news in treatment Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Characteristics and determinants of outcome of hospital-acquired
More informationRisk factors for methicillin-resistant Staphylococcus aureus bacteraemia differ depending on the control group chosen
Epidemiol. Infect. (2013), 141, 2376 2383. Cambridge University Press 2013 doi:10.1017/s0950268813000174 Risk factors for methicillin-resistant Staphylococcus aureus bacteraemia differ depending on the
More informationA Case of Probable Community Acquired Acinetobacter baumannii Pneumonia
A Case of Probable Community Acquired Acinetobacter baumannii Pneumonia 1 Division of Pulmonary Medicine, 2 Infectious Medicine, Department of Internal Medicine, Eulji University School of Medicine; 3
More informationMeasure Information Form
Release Notes: Measure Information Form Version 3.0b **NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE** Measure Set: Pneumonia (PN) Performance Measure Identifier: Measure Information Form
More informationESBL Positive E. coli and K. pneumoneae are Emerging as Major Pathogens for Urinary Tract Infection
ESBL Positive E. coli and K. pneumoneae are Emerging as Major Pathogens for Urinary Tract Infection Muhammad Abdur Rahim*, Palash Mitra*. Tabassum Samad*. Tufayel Ahmed Chowdhury*. Mehruba Alam Ananna*.
More informationGUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
Version 3.1 GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS Date ratified June 2008 Updated March 2009 Review date June 2010 Ratified by Authors Consultation Evidence base Changes
More informationPneumonia Antibiotic Guidance for Adults PAGL Inclusion Approved at January 2017 PGC
Pneumonia Antibiotic Guidance for Adults PAGL Inclusion Approved at January 2017 PGC APPROVED BY: Policy and Guidelines Committee TRUST REFERENCE: B9/2009 AWP Ref: AWP61 Date (approved): July 2008 REVIEW
More informationLearning Points. Raymond Blum, M.D. Antimicrobial resistance among gram-negative pathogens is increasing
Raymond Blum, M.D. Learning Points Antimicrobial resistance among gram-negative pathogens is increasing Infection with antimicrobial-resistant pathogens is associated with increased mortality, length of
More informationRISK FACTORS FOR PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE ACQUISITION IN PATIENTS IN BANGKOK
RISK FACTORS FOR PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE ACQUISITION IN PATIENTS IN BANGKOK Charungthai Dejthevaporn 1,2, Asda Vibhagool 1, Ammarin Thakkinstian 2, Sayomporn Sirinavin 2,3 and Malai
More informationORIGINAL ARTICLE /j x
ORIGINAL ARTICLE 10.1111/j.1469-0691.2005.01184.x Hospital outbreak caused by a carbapenem-resistant strain of Acinetobacter baumannii: patient prognosis and risk-factors for colonisation and infection
More informationAntimicrobial Cycling. Donald E Low University of Toronto
Antimicrobial Cycling Donald E Low University of Toronto Bad Bugs, No Drugs 1 The Antimicrobial Availability Task Force of the IDSA 1 identified as particularly problematic pathogens A. baumannii and
More informationHealth Care-Associated Pneumonia and Community-Acquired Pneumonia: a Single-Center Experience
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Oct. 2007, p. 3568 3573 Vol. 51, No. 10 0066-4804/07/$08.00 0 doi:10.1128/aac.00851-07 Copyright 2007, American Society for Microbiology. All Rights Reserved. Health
More informationPrevalence of Metallo-Beta-Lactamase Producing Pseudomonas aeruginosa and its antibiogram in a tertiary care centre
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 4 Number 9 (2015) pp. 952-956 http://www.ijcmas.com Original Research Article Prevalence of Metallo-Beta-Lactamase
More informationSeven-day antibiotic courses have similar efficacy to prolonged courses in severe community-acquired pneumonia a propensity-adjusted analysis
ORIGINAL ARTICLE INFECTIOUS DISEASES Seven-day antibiotic courses have similar efficacy to prolonged courses in severe community-acquired pneumonia a propensity-adjusted analysis G. Choudhury, P. Mandal,
More informationClinical and microbiological characterization of carbapenem-resistant Acinetobacter baumannii bloodstream infections
Journal of Medical Microbiology (2011), 60, 605 611 DOI 10.1099/jmm.0.029439-0 Clinical and microbiological characterization of carbapenem-resistant Acinetobacter baumannii bloodstream infections Joon
More informationIntroduction Extended spectrum beta-lactamase (ESBL)-producing bacilli. Methods. KPP Abhilash 1, Balaji Veeraraghavan 2, OC Abraham 1.
SUPPLEMENT TO JAPI december 2010 VOL. 58 13 Epidemiology and Outcome of Bacteremia Caused by Extended Spectrum Beta-Lactamase (Esbl)-producing Escherichia Coli and Klebsiella Spp. in a Tertiary Care Teaching
More informationInternational Journal of Antimicrobial Agents
International Journal of Antimicrobial Agents 35 (2010) 19 24 Contents lists available at ScienceDirect International Journal of Antimicrobial Agents journal homepage: http://www.elsevier.com/locate/ijantimicag
More informationBuilding Rapid Interventions to reduce antimicrobial resistance and overprescribing of antibiotics (BRIT)
Greater Manchester Connected Health City (GM CHC) Building Rapid Interventions to reduce antimicrobial resistance and overprescribing of antibiotics (BRIT) BRIT Dashboard Manual Users: General Practitioners
More informationSHC Clinical Pathway: HAP/VAP Flowchart
SHC Clinical Pathway: Hospital-Acquired and Ventilator-Associated Pneumonia SHC Clinical Pathway: HAP/VAP Flowchart v.08-29-2017 Diagnosis Hospitalization (HAP) Pneumonia develops 48 hours following: Endotracheal
More informationReceived 8 April 2012; received in revised form 15 December 2012; accepted 28 December 2012
Journal of Infection and Public Health (2013) 6, 216 221 Antimicrobial agent prescription patterns for chemotherapy-induced febrile neutropenia in patients with hematological malignancies at Sultan Qaboos
More informationDRUG-RESISTANT ACINETOBACTER BAUMANNII A GROWING SUPERBUG POPULATION. Cara Wilder Ph.D. Technical Writer March 13 th 2014
DRUG-RESISTANT ACINETOBACTER BAUMANNII A GROWING SUPERBUG POPULATION Cara Wilder Ph.D. Technical Writer March 13 th 2014 ATCC Founded in 1925, ATCC is a non-profit organization with headquarters in Manassas,
More informationFM - Male, 38YO. MRSA nasal swab (+) Due to positive MRSA nasal swab test, patient will be continued on Vancomycin 1500mg IV q12 for MRSA treatment...
Jillian O Keefe Doctor of Pharmacy Candidate 2016 September 15, 2015 FM - Male, 38YO HPI: Previously healthy male presents to ED febrile (102F) and in moderate distress ~2 weeks after getting a tattoo
More informationMulti-drug resistant Acinetobacter (MDRA) Surveillance and Control. Alison Holmes
Multi-drug resistant Acinetobacter (MDRA) Surveillance and Control Alison Holmes The organism and it s epidemiology Surveillance Control What is it? What is it? What is it? What is it? Acinetobacter :
More informationSuccessful stewardship in hospital settings
Successful stewardship in hospital settings Pr Charles-Edouard Luyt Service de Réanimation Institut de Cardiologie Groupe Hospitalier Pitié-Salpêtrière Université Pierre et Marie Curie, Paris 6 www.reamedpitie.com
More informationResearch & Reviews: Journal of Hospital and Clinical Pharmacy
Research & Reviews: Journal of Hospital and Clinical Pharmacy Empiric Antibiotic Prescribing For Community Acquired Pneumonia and Patient Characteristics Associated with Broad Spectrum Antibiotic Use Mirza
More informationPeriod of study: 12 Nov 2002 to 08 Apr 2004 (first subject s first visit to last subject s last visit)
Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency of Bayer's
More informationImpact of carbapenem resistance on clinical and economic outcomes among patients with Acinetobacter baumannii infection in Colombia
ORIGINAL ARTICLE BACTERIOLOGY Impact of carbapenem resistance on clinical and economic outcomes among patients with Acinetobacter baumannii infection in Colombia E. V. Lemos 1,2, F. P. de la Hoz 1, N.
More informationETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections
ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections Robin Isaacs Chief Medical Officer, Entasis Therapeutics Dr. Isaacs is a full-time employee of Entasis Therapeutics.
More informationReceived: February 29, 2008 Revised: July 22, 2008 Accepted: August 4, 2008
J Microbiol Immunol Infect. 29;42:317-323 In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections at a medical center
More informationAntibiotic stewardship in long term care
Antibiotic stewardship in long term care Shira Doron, MD Associate Professor of Medicine Division of Geographic Medicine and Infectious Diseases Tufts Medical Center Boston, MA Consultant to Massachusetts
More informationGuidelines for Treatment of Urinary Tract Infections
Guidelines for Treatment of Urinary Tract Infections Overview This document details the Michigan Hospital Medicine Safety (HMS) Consortium preferred antibiotic choices for treatment of uncomplicated and
More informationGuidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults)
Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults) Community Acquired Pneumonia Community Acquired Pneumonia 1) Is it pneumonia? ie new symptoms and signs of
More informationThe importance of infection control in the era of multi drug resistance
Dr. Kumar Consultant Infectious Diseases Physician Hospital Sungai buloh The importance of infection control in the era of multi drug resistance Nosocomial infections In Australian acute hospitals 200,000
More informationDETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams
DETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams Jan J. De Waele MD PhD Surgical ICU Ghent University Hospital Ghent, Belgium Disclosures Financial: consultancy for
More information2015 Antimicrobial Susceptibility Report
Gram negative Sepsis Outcome Programme (GNSOP) 2015 Antimicrobial Susceptibility Report Prepared by A/Professor Thomas Gottlieb Concord Hospital Sydney Jan Bell The University of Adelaide Adelaide On behalf
More informationTreatment for NTM: when how.and what next? Pr Claire Andréjak Respiratory and ICU Department University hospital, Amiens, France
Treatment for NTM: when how.and what next? Pr Claire Andréjak Respiratory and ICU Department University hospital, Amiens, France First step = To diagnose NTM disease One NTM positive sample NTM disease
More informationTreatment Guidelines and Outcomes of Hospital- Acquired and Ventilator-Associated Pneumonia
SUPPLEMENT ARTICLE Treatment Guidelines and Outcomes of Hospital- Acquired and Ventilator-Associated Pneumonia Antoni Torres, Miquel Ferrer, and Joan Ramón Badia Pneumology Department, Clinic Institute
More information